JP2019537582A - シナプス形成および神経突起形成を増強するための方法 - Google Patents

シナプス形成および神経突起形成を増強するための方法 Download PDF

Info

Publication number
JP2019537582A
JP2019537582A JP2019522710A JP2019522710A JP2019537582A JP 2019537582 A JP2019537582 A JP 2019537582A JP 2019522710 A JP2019522710 A JP 2019522710A JP 2019522710 A JP2019522710 A JP 2019522710A JP 2019537582 A JP2019537582 A JP 2019537582A
Authority
JP
Japan
Prior art keywords
subject
dspbn
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537582A5 (enExample
Inventor
ディー． コピケ，リチャード
ディー． コピケ，リチャード
リー，ウェイ
Original Assignee
ハフ イアー インスティテュート
ハフ イアー インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハフ イアー インスティテュート, ハフ イアー インスティテュート filed Critical ハフ イアー インスティテュート
Publication of JP2019537582A publication Critical patent/JP2019537582A/ja
Publication of JP2019537582A5 publication Critical patent/JP2019537582A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2019522710A 2016-10-31 2017-10-27 シナプス形成および神経突起形成を増強するための方法 Pending JP2019537582A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662415101P 2016-10-31 2016-10-31
US62/415,101 2016-10-31
US201762488740P 2017-04-22 2017-04-22
US62/488,740 2017-04-22
US201762510596P 2017-05-24 2017-05-24
US62/510,596 2017-05-24
US201762550345P 2017-08-25 2017-08-25
US62/550,345 2017-08-25
PCT/US2017/058834 WO2018081614A1 (en) 2016-10-31 2017-10-27 Methods for enhancing synaptogenesis and neuritogenesis

Publications (2)

Publication Number Publication Date
JP2019537582A true JP2019537582A (ja) 2019-12-26
JP2019537582A5 JP2019537582A5 (enExample) 2020-12-03

Family

ID=62020809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522710A Pending JP2019537582A (ja) 2016-10-31 2017-10-27 シナプス形成および神経突起形成を増強するための方法

Country Status (5)

Country Link
US (2) US10576125B2 (enExample)
EP (1) EP3532042A4 (enExample)
JP (1) JP2019537582A (enExample)
CN (1) CN110248650A (enExample)
WO (1) WO2018081614A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522282A (ja) 2018-04-27 2021-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ リソソーム蓄積障害の治療
US12076330B2 (en) 2018-04-27 2024-09-03 The Regents Of The University Of California Inhibition of lipofuscin aggregation by molecular tweezers
EP3787750A1 (en) * 2018-05-03 2021-03-10 Hough Ear Institute Methods for reducing accumulated pathologic tau protein
JP2022500407A (ja) * 2018-09-12 2022-01-04 ハフ イアー インスティテュート 人工内耳手術に伴う難聴の治療方法
CA3134875A1 (en) * 2019-03-26 2020-10-01 Tonix Pharma Holdings Limited Salt forms of s-(n, n-diethylcarbamoyl)glutathione
US12390510B2 (en) 2019-05-29 2025-08-19 Massachusetts Eye And Ear Infirmary Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2)
CN112939823A (zh) * 2019-12-10 2021-06-11 中国石油天然气股份有限公司 泥页岩抑制剂制备方法及抑制剂的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014511374A (ja) * 2011-02-04 2014-05-15 ハフ イヤ インスティテュート 外傷性脳損傷を処置する方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US6064064A (en) * 1996-03-01 2000-05-16 Fire Sentry Corporation Fire detector
WO2000018407A1 (en) 1998-09-25 2000-04-06 Cephalon, Inc. Methods for preventing/treating damage to sensory hair cells and cochlear neurons
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
TR201911199T4 (tr) 2009-03-27 2019-08-21 Moleac Pte Ltd Hücre büyümesini arttırmak için tedavi.
ES2563777T3 (es) * 2009-08-24 2016-03-16 Hough Ear Institute Compuestos de nitrona para tratar la pérdida auditiva sensorineural
WO2014014828A1 (en) * 2012-07-16 2014-01-23 Cornell University Nicotinamide riboside to treat hearing loss
AU2013312358B2 (en) 2012-09-07 2018-08-09 Massachusetts Eye & Ear Infirmary Treating hearing loss
US9718805B2 (en) * 2013-06-04 2017-08-01 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
US20180256756A1 (en) * 2015-09-18 2018-09-13 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014511374A (ja) * 2011-02-04 2014-05-15 ハフ イヤ インスティテュート 外傷性脳損傷を処置する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEARING RESEARCH, vol. 285, JPN6021040537, 2011, pages 29 - 39, ISSN: 0004803587 *
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. Vol.2016, Article ID 4159357, JPN6021040538, pages 1 - 15, ISSN: 0004803588 *

Also Published As

Publication number Publication date
US20180117115A1 (en) 2018-05-03
CN110248650A (zh) 2019-09-17
EP3532042A4 (en) 2020-06-24
WO2018081614A1 (en) 2018-05-03
US10576125B2 (en) 2020-03-03
EP3532042A1 (en) 2019-09-04
US20200164021A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
JP2019537582A (ja) シナプス形成および神経突起形成を増強するための方法
Sivak The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease
Kuehn et al. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies.
US20220387438A1 (en) Calcineurin inhibitors of the setron family for the treatment of hearing loss
US20210308120A1 (en) Use of Amitriptyline for Blocking Brain Hemichannels and Method for Potentiating its Effect in Vivo
US20210236450A1 (en) Methods and Compositions for Preventing and Treating Auditory Dysfunctions
JP6904612B2 (ja) 蝸牛シナプス障害を処置する方法
Hosseinzadeh et al. Molecular aspects of melatonin treatment in tinnitus: a review
US20180235934A1 (en) Noradrenergic drug treatment of obstructive sleep apnea
AU2006341983A1 (en) Use of an NMDA receptor antagonist the treatment of tinnitus induced by cochlear excitotoxicity
US10925858B2 (en) S-nitrosoglutathione (GSNO) and GSNO reductase inhibitors for use in therapy
KR20180081807A (ko) 알츠하이머 질환 및 관련 장애의 치료 방법
JP2023553414A (ja) ドライ型加齢黄斑変性症（ａｍｄ）治療用組成物
US20210038589A1 (en) Uses, compositions and methods
JP2021523126A (ja) 蓄積した病理学的Ｔａｕタンパク質を低減する方法
CN104780917B (zh) 基于巴氯芬和阿坎酸的黄斑变性病症的疗法
CN113855803B (zh) Prmt5抑制剂在用于制备听力保护药物中的用途
HK40012341A (en) Methods for enhancing synaptogenesis and neuritogenesis
US20240294925A1 (en) Method of Treatment for Auditory Dysfunction
Chittoor Understanding and evaluating the potential of heat shock pathway in treatment of PMP22-linked neuropathies
HK1250343B (en) Azasetron for use in the treatment of hearing loss

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220621